Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp105 | Diabetes therapy & complications 2 | ECE2017

Ceramide synthase 6 inhibition as a novel therapeutic approach for obesity and type 2 diabetes

Bielohuby Maximilian , Prakash Surya , Brunner Bodo , Pfenninger Anja , Werner Ulrich , Turpin-Nolan Sarah , Bruning Jens , Tennagels Norbert

Excess consumption of saturated fatty acids may lead to an increased production of ceramides that contribute to development of insulin resistance and type 2 diabetes. Substantial research demonstrated that inhibition of ceramide biosynthesis ameliorates atherosclerosis, hepatic steatosis, insulin resistance and obesity. However, as ceramides and their sphingolipid products are involved in multiple fundamental cellular processes, concerns exist about possible risks or adverse e...

ea0056gp110 | Diabetes Translational | ECE2018

Knock-down of class 2a histone deacetylases (HDACs) in hepatocytes of healthy mice does not affect gluconeogenesis but is associated with increased hematopoiesis

Bielohuby Maximilian , Raichur Suryaprakash , Stolte Manuela , Hemmann Ulrike , Gorgens Sven W , Wohlfart Paulus , Jahn-Hofmann Kerstin , Brunner Bodo , Tennagels Norbert

Class 2a HDACs (i.e. HDAC 4, 5, 7 and 9) are involved in the regulation of gluconeogenesis and accordingly, their inhibition has been shown to result in lower blood glucose and improved pyruvate tolerance in diabetic mice. However, pan-inhibition of HDACs is not a viable approach for chronic treatment of type 2 diabetes (T2D) due to induction of severe side effects in various tissues. We now have investigated in vitro and in vivo efficacy and safety of a live...